Indications for DAPTACEL:

Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age (before 7th birthday).


Not recommended.


Each dose is 0.5mL IM in anterolateral thigh or deltoid. 5-dose series: Give 1st dose preferably at 2 months of age (may give as early as 6 weeks of age); then give 2nd dose 6–8 weeks later, then give 3rd dose 6–8 weeks later; give 4th dose at 15–20 months of age; give 5th dose at 4–6 years of age. May be used to complete primary series in children who received ≥1 whole-cell DTP doses: see full labeling.


Anaphylaxis associated with any previous dose. Encephalopathy within 7 days after a previous pertussis-containing vaccine. Progressive neurologic disorders (eg, infantile spasms, uncontrolled epilepsy, progressive encephalopathy).


Fever (≥105°F within 48 hours), persistent inconsolable crying (≥3 hours within 48 hours), shock (within 48 hours), seizures (within 3 days), Guillain-Barre Syndrome (within 6 weeks) of previous tetanus toxoid-containing vaccine. Seizure risk (may give antipyretic). Have epinephrine inj (1:1000) available. Immunocompromised. Latex allergy. Pregnancy (Cat.C).

Pharmacologic Class:



Concomitant vaccines: see full labeling. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.

Adverse Reactions:

Fussiness/irritability, inconsolable crying, lethargy, fever, inj site reactions.

How Supplied:

Single-dose vials (0.5mL)—1, 5, 10

Pricing for DAPTACEL

0.5ml vial (Qty: 1)
Appx. price $37